- Home
- BGM vs KRON Comparison
BGM vs KRON Comparison
Compare BGM & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGM
- KRON
- Stock Information
- Founded
- BGM 2019
- KRON 2017
- Country
- BGM China
- KRON United States
- Employees
- BGM N/A
- KRON N/A
- Industry
- BGM
- KRON Medicinal Chemicals and Botanical Products
- Sector
- BGM
- KRON Health Care
- Exchange
- BGM NYSE
- KRON Nasdaq
- Market Cap
- BGM 52.8M
- KRON 60.3M
- IPO Year
- BGM 2021
- KRON 2020
- Fundamental
- Price
- BGM $6.61
- KRON $0.85
- Analyst Decision
- BGM
- KRON Buy
- Analyst Count
- BGM 0
- KRON 3
- Target Price
- BGM N/A
- KRON $1.63
- AVG Volume (30 Days)
- BGM 18.6K
- KRON 63.6K
- Earning Date
- BGM 08-14-2024
- KRON 11-13-2024
- Dividend Yield
- BGM N/A
- KRON N/A
- EPS Growth
- BGM N/A
- KRON N/A
- EPS
- BGM N/A
- KRON N/A
- Revenue
- BGM $29,870,461.00
- KRON $8,412,000.00
- Revenue This Year
- BGM N/A
- KRON $52.58
- Revenue Next Year
- BGM N/A
- KRON N/A
- P/E Ratio
- BGM N/A
- KRON N/A
- Revenue Growth
- BGM N/A
- KRON 172.76
- 52 Week Low
- BGM $1.78
- KRON $0.69
- 52 Week High
- BGM $8.96
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- BGM 37.44
- KRON 42.36
- Support Level
- BGM $6.51
- KRON $0.83
- Resistance Level
- BGM $7.82
- KRON $0.98
- Average True Range (ATR)
- BGM 0.44
- KRON 0.06
- MACD
- BGM -0.13
- KRON -0.01
- Stochastic Oscillator
- BGM 22.42
- KRON 27.14
About BGM QILIAN INTERNATIONAL HLDG GROUP LTD
BGM Group Ltd formerly, Qilian International Holding Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.